搜尋
Valneva SE
VALN添加自選
5.225USD
+0.135+2.65%
收盤 07/02, 13:00（美東）報價延遲15分鐘
453.93M總市值
虧損本益比TTM
關鍵數據
5.275今開
5.430最高
19.02K成交量
虧損本益比TTM
7.51本益比動
--股利TTM
0.02%換手率
5.090昨收
5.160最低
74.53K成交額
虧損本益比靜
5.04市淨率
0.00%股息率 TTM
-32.32%ROA
12.25052週最高
1.17量比
-12.25M淨利潤
86.88M總股本
-1.3936每股盈餘TTM
1.75Beta
-109.57%ROE
5.06052週最低
5.30%振幅
15.29%毛利率
453.93M總市值
-4.12回報/風險
2.48%風險率
TradingKey Valneva SE股票評分
單位: USD 更新時間: 2026-07-02操作建議
Valneva SE當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名129/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為12.20。中期看，股價處於下降通道。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Valneva SE評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Valneva SE亮點
亮點風險
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
業績高增長
公司營業收入穩步增長，連續3年增長33.76%
利潤高增長
公司淨利潤處於行業前列，最新年度總收入205.61M美元
估值高估
公司最新PE估值-3.75，處於3年歷史高位
機構減倉
最新機構持股5.21M股，環比減少5.60%
活躍度降低
近期活躍度降低，過去20天平均換手率-0.57
分析師目標
基於
4
分析師
買入
評級
12.200
目標均價
+139.69%
漲幅空間
Valneva SE新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Valneva SE簡介
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
公司代碼VALN
公司Valneva SE
CEOLingelbach (Thomas)
網址https://valneva.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
常見問題
Valneva SE(VALN)的當前股價是多少？
Valneva SE(VALN)的當前股價是 5.22。
Valneva SE 的股票代碼是什麼？
Valneva SE的股票代碼是VALN。
Valneva SE股票的52週最高點是多少？
Valneva SE股票的52週最高點是12.25。
Valneva SE股票的52週最低點是多少？
Valneva SE股票的52週最低點是5.06。
Valneva SE的市值是多少？
Valneva SE的市值是453.93M。
現在Valneva SE(VALN)的股票是買入、持有還是賣出？
根據分析師評級，Valneva SE(VALN)的總體評級為買入，目標價格為12.20。
Valneva SE(VALN)股票的每股收益（EPS TTM）是多少
Valneva SE(VALN)股票的每股收益（EPS TTM）是-1.61。